Safe prescription of systemic antineoplastic treatment in oncology: integrative literature review
The objective of this study was to identify the available evidence on the parameters that should be considered to improve the quality and safety of the prescription of systemic antineoplastic treatment. This is an integrative review carried out in the EMBASE, LILACS, and PubMed databases, from 2015...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Revinter Publicações Ltda.
2022-10-01
|
| Series: | Brazilian Journal of Oncology |
| Subjects: | |
| Online Access: | https://www.brazilianjournalofoncology.com.br/details/187/en-US/safe-prescription-of-systemic-antineoplastic-treatment-in-oncology--integrative-literature-review |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849306755882811392 |
|---|---|
| author | Fabiola Vasconcelos Alves Renata Cristina de Campos Pereira Silveira Flavia Oliveira de Almeida Marques da Cruz Elaine Barros Ferreira Paula Elaine Diniz dos Reis |
| author_facet | Fabiola Vasconcelos Alves Renata Cristina de Campos Pereira Silveira Flavia Oliveira de Almeida Marques da Cruz Elaine Barros Ferreira Paula Elaine Diniz dos Reis |
| author_sort | Fabiola Vasconcelos Alves |
| collection | DOAJ |
| description | The objective of this study was to identify the available evidence on the parameters that should be considered to improve the quality and safety of the prescription of systemic antineoplastic treatment. This is an integrative review carried out in the EMBASE, LILACS, and PubMed databases, from 2015 to 2019. The methodological quality of the included studies was assessed by the tools of the Joanna Briggs Institute. Eight studies were included, of which 5 addressed adverse events related to systemic antineoplastic treatment, including 4,970 patients treated with immunotherapy, target therapy, and chemotherapy. One study assessed the safety of prescribing antineoplastic agents and 2 studies addressed pharmacovigilance and risk management by assessing treatment- related adverse effects. Chemotherapy, target therapy, and immunotherapy have different toxicity profiles. The evidence suggests that assessment of treatment toxicity as well as risk management should be considered to improve the quality and safety of prescribing systemic antineoplastic treatment. |
| format | Article |
| id | doaj-art-23b09bcb3bc543b18908d927a7f0d7d5 |
| institution | Kabale University |
| issn | 2526-8732 |
| language | English |
| publishDate | 2022-10-01 |
| publisher | Thieme Revinter Publicações Ltda. |
| record_format | Article |
| series | Brazilian Journal of Oncology |
| spelling | doaj-art-23b09bcb3bc543b18908d927a7f0d7d52025-08-20T03:54:58ZengThieme Revinter Publicações Ltda.Brazilian Journal of Oncology2526-87322022-10-01180010.5935/2526-8732.20220300Safe prescription of systemic antineoplastic treatment in oncology: integrative literature reviewFabiola Vasconcelos Alves0https://orcid.org/0000-0001-5820-6296Renata Cristina de Campos Pereira Silveira1Flavia Oliveira de Almeida Marques da Cruz2Elaine Barros Ferreira3Paula Elaine Diniz dos Reis4University of Brasilia, Faculty of Health Sciences - Brasilia - Federal District - BrazilUniversity of São Paulo, Department of General and Specialized Nursing - Ribeirão Preto - São Paulo - BrazilUniversity of Federal District, University Center of Federal District - Brasilia - Federal District - BrazilUniversity of Brasilia, Faculty of Health Sciences - Brasilia - Federal District - BrazilUniversity of Brasilia, Faculty of Health Sciences - Brasilia - Federal District - BrazilThe objective of this study was to identify the available evidence on the parameters that should be considered to improve the quality and safety of the prescription of systemic antineoplastic treatment. This is an integrative review carried out in the EMBASE, LILACS, and PubMed databases, from 2015 to 2019. The methodological quality of the included studies was assessed by the tools of the Joanna Briggs Institute. Eight studies were included, of which 5 addressed adverse events related to systemic antineoplastic treatment, including 4,970 patients treated with immunotherapy, target therapy, and chemotherapy. One study assessed the safety of prescribing antineoplastic agents and 2 studies addressed pharmacovigilance and risk management by assessing treatment- related adverse effects. Chemotherapy, target therapy, and immunotherapy have different toxicity profiles. The evidence suggests that assessment of treatment toxicity as well as risk management should be considered to improve the quality and safety of prescribing systemic antineoplastic treatment.https://www.brazilianjournalofoncology.com.br/details/187/en-US/safe-prescription-of-systemic-antineoplastic-treatment-in-oncology--integrative-literature-reviewantineoplastic agentsimmunotherapydrug-related side effects and adverse reactionspatient safety |
| spellingShingle | Fabiola Vasconcelos Alves Renata Cristina de Campos Pereira Silveira Flavia Oliveira de Almeida Marques da Cruz Elaine Barros Ferreira Paula Elaine Diniz dos Reis Safe prescription of systemic antineoplastic treatment in oncology: integrative literature review Brazilian Journal of Oncology antineoplastic agents immunotherapy drug-related side effects and adverse reactions patient safety |
| title | Safe prescription of systemic antineoplastic treatment in oncology: integrative literature review |
| title_full | Safe prescription of systemic antineoplastic treatment in oncology: integrative literature review |
| title_fullStr | Safe prescription of systemic antineoplastic treatment in oncology: integrative literature review |
| title_full_unstemmed | Safe prescription of systemic antineoplastic treatment in oncology: integrative literature review |
| title_short | Safe prescription of systemic antineoplastic treatment in oncology: integrative literature review |
| title_sort | safe prescription of systemic antineoplastic treatment in oncology integrative literature review |
| topic | antineoplastic agents immunotherapy drug-related side effects and adverse reactions patient safety |
| url | https://www.brazilianjournalofoncology.com.br/details/187/en-US/safe-prescription-of-systemic-antineoplastic-treatment-in-oncology--integrative-literature-review |
| work_keys_str_mv | AT fabiolavasconcelosalves safeprescriptionofsystemicantineoplastictreatmentinoncologyintegrativeliteraturereview AT renatacristinadecampospereirasilveira safeprescriptionofsystemicantineoplastictreatmentinoncologyintegrativeliteraturereview AT flaviaoliveiradealmeidamarquesdacruz safeprescriptionofsystemicantineoplastictreatmentinoncologyintegrativeliteraturereview AT elainebarrosferreira safeprescriptionofsystemicantineoplastictreatmentinoncologyintegrativeliteraturereview AT paulaelainedinizdosreis safeprescriptionofsystemicantineoplastictreatmentinoncologyintegrativeliteraturereview |